Article
Oncology
Jianping Yang, Chunjun Li, Yong Tang, Fang Guo, Yu Chen, Wenqi Luo, Xiaoyu Chen, Yun Ma, Lixia Zeng
Summary: The markers MI and Ki-67 are important indicators of histopathology and cell proliferation, and can be easily measured with good reproducibility. These markers may play a meaningful role in assigning the pathological grade of UBC.
Article
Urology & Nephrology
Radoslaw Piszczek, Wojciech Krajewski, Jose D. Subiela, Francesco Del Giudice, Lukasz Nowak, Joanna Chorbinska, Marco Moschini, Alexandra Masson-Lecomte, Sonia Bebane, Alessia Cimadamore, Elisabeth Grobet-Jeandin, Morgan Roupret, David D'Andrea, Riccardo Mastroianni, Beatriz Gutierrez Hidalgo, Juan Gomez Rivas, Keiichiro Mori, Francesco Soria, Ekaterina Laukhtina, Andrea Mari, Simone Albisinni, Andrea Gallioli, Laura S. Mertens, Renate Pichler, Gautier Marcq, Jan Laszkiewicz, Agnieszka Halon, Diego M. Carrion, Murat Akand, Benjamin Pradere, Shahrokh F. Shariat, Juan Palou, Marko Babjuk, Javier Burgos Revilla, Bartosz Malkiewicz, Tomasz Szydelko
Summary: The study found that the RFS of T1LG bladder cancer was comparable to other NMIBC subpopulations, but the PFS was significantly better than in T1HG NMIBC. The EAU 2021 scoring model heterogeneously categorized the risk of progression in T1LG tumors.
MINERVA UROLOGY AND NEPHROLOGY
(2023)
Article
Urology & Nephrology
Chiara Lonati, Philipp Baumeister, Luca Afferi, Andrea Mari, Andrea Minervini, Wojciech Krajewski, Sosan Azizi, Kees Hendricksen, Alberto Martini, Andrea Necchi, Francesco Montorsi, Alberto Briganti, Renzo Colombo, Alessandro Tafuri, Alessandro Antonelli, Maria Angela Cerruto, Morgan Roupret, Alexandra Masson-Lecomte, Ekaterina Laukhtina, David D'Andrea, Shahrokh F. Shariat, Francesco Soria, Giancarlo Marra, Paolo Gontero, Roberto Contieri, Rodolfo Hurle, Anne Sophie Valiquette, M. Carmen Mir, Stefania Zamboni, Claudio Simeone, Tobias Klatte, Jeremy Yuen-Chun Teoh, Soichiro Yoshida, Yasuhisa Fujii, Roberto Carando, Gerald B. Schulz, Livio Mordasini, Agostino Mattei, Marco Moschini
Summary: This study retrospectively analyzed the treatment outcomes of 119 T1 HG MPBC patients and found no significant difference in cancer-specific mortality and overall mortality between immediate radical cystectomy and conservative management. The rates of disease recurrence and progression after conservative management were relatively high, and concomitant lymphovascular invasion was an independent predictor.
EUROPEAN UROLOGY FOCUS
(2022)
Article
Oncology
Simon C. Baker, Andrew S. Mason, Raphael G. Slip, Pontus Eriksson, Gottfrid Sjodahl, Ludwik K. Trejdosiewicz, Jennifer Southgate
Summary: This study found that using interferon gamma (IFN gamma) in the treatment of bladder cancer can improve patients' survival rate, while treatments targeting immune checkpoints have limited effectiveness. The research also discovered that IFN gamma can regulate the expression of immune inhibitory genes, providing new therapeutic targets to enhance immunotherapy.
Article
Urology & Nephrology
Aleksander Slusarczyk, Karolina Garbas, Piotr Zapala, Lukasz Zapala, Piotr Radziszewski
Summary: The study aimed to evaluate the outcomes of high-grade T1 non-muscle-invasive bladder cancer treatment in elderly patients over 80 years old. Results indicated that BCG therapy significantly improved cancer-specific survival and reduced recurrence rates in octogenarians with T1HG bladder cancer, despite advanced age and comorbidities.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2021)
Article
Oncology
Makito Miyake, Nobutaka Nishimura, Kota Iida, Tomomi Fujii, Ryoma Nishikawa, Shogo Teraoka, Atsushi Takenaka, Hiroshi Kikuchi, Takashige Abe, Nobuo Shinohara, Eijiro Okajima, Takuto Shimizu, Shunta Hori, Norihiko Tsuchiya, Takuya Owari, Yasukiyo Murakami, Rikiya Taoka, Takashi Kobayashi, Takahiro Kojima, Naotaka Nishiyama, Hiroshi Kitamura, Hiroyuki Nishiyama, Kiyohide Fujimoto
Summary: The study investigated the outcomes of bladder UC patients with DD or VMs treated with intravesical BCG, finding that concomitant VMs were more likely to result in cancer-specific death. The risk associated with VMs was significant for cancer-specific mortality only, not affecting recurrence-free or progression-free survival rates.
Article
Urology & Nephrology
Matteo Ferro, Michele Marchioni, Giuseppe Lucarelli, Mihai D. Vartolomei, Francesco Soria, Daniela Terracciano, Francesco A. Mistretta, Stefano Luzzago, Carlo Buonerba, Francesco Cantiello, Andrea Mari, Andrea Minervini, Alessandro Veccia, Alessandro Antonelli, Gennaro Musi, Rodolfo Hurle, Gian M. Busetto, Francesco Del Giudice, Benjamin Chung, Francesco Berardinelli, Sisto Perdona, Paola Del Prete, Vincenzo Mirone, Marco Borghesi, Angelo Porreca, Pierluigi Bove, Riccardo Autorino, Nicolae Crisan, Abdal R. Abu Farhan, Michele Battaglia, Pasquale Ditonno, Giorgio Russo, Matteo Muto, Rocco Damiano, Matteo Manfredi, Francesco Porpiglia, Ottavio De Cobelli, Luigi Schips
Summary: The study found that the use of statins may increase the recurrence rate of high-grade bladder cancer, but does not have an independent effect on overall mortality and disease progression rates. On the other hand, statin use can reduce the risk of recurrence and may be beneficial for recurrence-free survival in patients.
MINERVA UROLOGY AND NEPHROLOGY
(2021)
Article
Cell Biology
Scott J. Weir, Prasad Dandawate, David Standing, Sangita Bhattacharyya, Prabhu Ramamoorthy, Parthasarathy Rangarajan, Robyn Wood, Amanda E. Brinker, Benjamin L. Woolbright, Mehmet Tanol, Tammy Ham, William McCulloch, Michael Dalton, Gregory A. Reed, Michael J. Baltezor, Roy A. Jensen, John A. Taylor, Shrikant Anant
Summary: CPX-POM shows anti-proliferative and anti-clonogenic effects on high-grade urothelial cancer by inhibiting the Notch signaling pathway. In a mouse bladder cancer model, CPX-POM treatment significantly reduces tumor volume and lowers the stage of bladder cancer, accompanied by a decrease in the proliferation index.
CELL DEATH & DISEASE
(2021)
Article
Multidisciplinary Sciences
Jeffrey S. Damrauer, Wolfgang Beckabir, Jeff Klomp, Mi Zhou, Elizabeth R. Plimack, Matthew D. Galsky, Petros Grivas, Noah M. Hahn, Peter H. O'Donnell, Gopa Iyer, David Quinn, Benjamin G. Vincent, Diane Zipursky Quale, Sara E. Wobker, Katherine A. Hoadley, William Y. Kim, Matthew Milowsky
Summary: UC-GENOME is a genomic analysis study on metastatic urothelial carcinoma, which identified features associated with benefit to chemotherapy and immune checkpoint inhibition, and developed a computational model for predicting immune checkpoint inhibitor response. This study provides a foundation for better understanding the biology of urothelial carcinoma.
NATURE COMMUNICATIONS
(2022)
Article
Pathology
Jacqueline Fontugne, Evanguelos Xylinas, Clementine Krucker, Victoria Dixon, Clarice S. Groeneveld, Ugo Pinar, Gianluigi Califano, Margot Bucau, Jerome Verine, Francois Desgrandchamps, Jean-Francois Hermieu, Francois Radvanyi, Yves Allory, Alexandra Masson-Lecomte
Summary: Through the study of upper tract urothelial carcinomas (UTUCs), we found that the consensus classification can reliably classify UTUCs and highlight intratumoral molecular heterogeneity, with a higher proportion of luminal papillary subtype compared to muscle-invasive bladder cancer (MIBC).
Article
Medicine, General & Internal
Long Huang, Kang Jia, Kai Yao, Dongliang Liu, Yan Xu, Quanda Liu
Summary: The impact of neoadjuvant chemotherapy (NAC) on survival outcomes in non-muscle-invasive bladder cancer (NMIBC) patients undergoing radical cystectomy (RC) remains unclear. This study found that NAC did not significantly improve overall survival (OS) in NMIBC patients undergoing RC, but showed potential survival advantage in patients with lymph node metastasis.
Review
Oncology
Deepika Kumar, Adebowale J. Adeniran
Summary: This review focuses on micropapillary urothelial carcinoma, discussing its biology, histopathologic characteristics, genetic and molecular features, diagnosis, clinical management, and future research directions. Recent studies have shown moderate interobserver reproducibility in the diagnostic criteria, with the most reproducible criteria being the presence of multiple nests in the same lacunar spaces. There have also been reports of high rates of intratumoral heterogeneity of ERBB2 amplification in tumors containing both micropapillary and classic urothelial components. Accurate recognition and reporting of this pattern is crucial for optimal management, and further exploration of therapeutic strategies based on molecular and genetic findings is needed.
CURRENT ONCOLOGY REPORTS
(2022)
Review
Oncology
Jingyu Zang, Kaiyan Ye, Yang Fei, Ruiyun Zhang, Haige Chen, Guanglei Zhuang
Summary: Advancements in technology have enabled the use of single-cell analysis in characterizing the multicellular ecosystem of UBC, providing insights for more effective immune-based therapies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Kimberley D. Katleba, Maria-Malvina Tsamouri, Maitreyee Jathal, Han Bit Baek, Rebecca B. Armenta, Clifford G. Tepper, Gino Cortopassi, Paramita M. Ghosh, Maria Mudryj
Summary: The sex disparity in bladder cancer implies the involvement of androgen receptor (AR) signaling in these malignancies. Different forms of AR regulate partially overlapping transcriptional programs, including the decrease of mTOR and the increase of hypoxia-regulated transcripts. Niclosamide, identified as an ATPase inhibitor in a compound library, shows potential for targeting the AR downstream vulnerability and limiting bladder cancer.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Syed N. Rahman, Soum D. Lokeshwar, Jamil S. Syed, Juan F. Javier-Desloges, Benjamin H. Press, Ankur U. Choksi, Pawel Rajwa, Benjamin Pradere, Guillaume Ploussard, Joseph W. Kim, Thomas F. Monaghan, Joseph R. Renzulli, Shahrokh F. Shariat, Michael S. Leapman
Summary: There is a lack of consensus on the effectiveness of neoadjuvant platinum-based chemotherapy in patients with micropapillary variant urothelial carcinoma (MVUC) prior to radical cystectomy. This study examined the association between neoadjuvant chemotherapy (NAC) and pathologic response among MVUC patients and non-variant bladder urothelial carcinoma (UC) patients. The findings provide important insights into the efficacy of neoadjuvant chemotherapy in patients with MVUC.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Oncology
Ahmad Y. Abuhelwa, Joaquim Bellmunt, Ganessan Kichenadasse, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich, Ashley M. Hopkins
Summary: This study validated and enhanced the discrimination ability of the Bellmunt risk score for immune checkpoint inhibitor therapy in patients with urothelial carcinoma. The inclusion of C-reactive protein in the Bellmunt score improved its performance and allowed for better patient stratification in clinical trials.
CLINICAL GENITOURINARY CANCER
(2022)
Article
Oncology
Kenneth Softness, Sumedh Kaul, Aaron Fleishman, Jason Efstathiou, Joaquim Bellmunt, Simon P. Kim, Ruslan Korets, Peter Chang, Andrew Wagner, Aria F. Olumi, Boris Gershman
Summary: In this study, the comparative effectiveness of radical cystectomy (RC) and trimodality therapy (TMT) for muscle-invasive bladder cancer was evaluated using observational data. The results showed no statistically significant difference in overall survival (OS) between RC and TMT. However, when examining heterogeneity of treatment effects, RC appeared to be associated with improved OS only for patients with cT3 disease.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Oncology
T. Powles, J. Bellmunt, E. Comperat, M. De Santis, R. Huddart, Y. Loriot, A. Necchi, B. P. Valderrama, A. Ravaud, S. F. Shariat, B. Szabados, M. S. van der Heijden, S. Gillessen
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Joep J. de Jong, Begona P. Valderrama, Julia Perera, Nuria Juanpere, Paloma Cejas, Henry Long, M. Mar Alba, Ewan A. Gibb, Joaquim Bellmunt
Summary: By analyzing the lncRNA expression profiles, we identified a subgroup of aggressive HGT1 bladder cancer with micropapillary histology. These findings suggest that lncRNAs can facilitate the identification of aggressive micropapillary-like tumors, potentially improving patient management.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Alejo Rodriguez-Vida, Pablo Maroto, Albert Font, Cristina Martin, Begona Mellado, Alex Corbera, Mayra Orrillo, Oscar Reig, Rosa Querol, Alejandro Rios-Hoyo, Laia Cano, Judith Alonso, Gemma Martinez, Susana Galtes, Alvaro Taus, Maria Martinez-Garcia, Nuria Juanpere, Oscar Juan, Joaquim Bellmunt
Summary: This study investigated the safety and efficacy of avelumab plus carboplatin in mCRPC patients. Despite the significant treatment-related adverse events, this therapy was associated with a prolonged overall survival in heavily pretreated patients.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Cora N. Sternberg, Daniel P. Petrylak, Joaquim Bellmunt, Hiroyuki Nishiyama, Andrea Necchi, Howard Gurney, Jae-Lyun Lee, Michiel S. van der Heijden, Eli Rosenbaum, Nicolas Penel, See-Tong Pang, Jian-Ri Li, Xavier Garcia del Muro, Florence Joly, Zsuzsanna Papai, Weichao Bao, Peter Ellinghaus, Chengxing Lu, Mitchell Sierecki, Sabine Coppieters, Keiko Nakajima, Tatiane Cristine Ishida, David Quinn
Summary: The purpose of this study was to assess the efficacy and safety of rogaratinib compared to chemotherapy in patients with FGFR-positive advanced/metastatic UC. The results showed comparable overall survival and response rates between rogaratinib and chemotherapy, with manageable side effects. Exploratory analysis suggested that FGFR3 gene alterations may be better predictors of rogaratinib response in FGFR-altered UC patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Thomas Powles, Se Hoon Park, Claudia Caserta, Begona P. Valderrama, Howard Gurney, Anders Ullen, Yohann Loriot, Srikala S. S. Sridhar, Cora N. N. Sternberg, Joaquim Bellmunt, Jeanny B. B. Aragon-Ching, Jing Wang, Bo Huang, Robert J. J. Laliberte, Alessandra di Pietro, Petros Grivas
Summary: Clinical trials often have multiple endpoints that mature at different times. Clinical Trial Updates provide the opportunity to disseminate additional results from studies for which the primary endpoint has already been reported.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Urology & Nephrology
Chris Labaki, Eddy Saad, Toni K. Choueiri, Joaquim Bellmunt
Article
Oncology
Thomas Seisen, Muhieddine Labban, Stuart R. R. Lipsitz, Mark A. A. Preston, Matthew Mossanen, Joaquim Bellmunt, Morgan Roupret, Toni K. K. Choueiri, Adam S. S. Kibel, Maxine Sun, Quoc-Dien Trinh
Summary: This study examined the ecological association between tobacco smoking prevalence and bladder cancer incidence and found that the association was not significant. However, there was a significant association between tobacco smoking prevalence and lung cancer incidence.
Article
Pathology
Laura Segales, Nuria Juanpere, Nerea Gallarin, Marta Lorenzo, David Lopez, Julia Perera-Bel, Alejo Rodriguez-Vida, Lluis Fumado, Lluis Cecchini, Joaquim Bellmunt, Josep Lloreta-Trull, Silvia Hernandez-Llodra
Summary: The impact of tumor focality on prostate cancer prognosis has been investigated. The study found relevant and consistent molecular differences between unifocal and multifocal prostate cancer. An immunohistochemical panel may be useful in predicting the outcome of multifocal prostate cancer cases.
Review
Oncology
Rosa Nadal, Begona P. Valderrama, Joaquim Bellmunt
Summary: Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains difficult to cure, but the availability of maintenance therapy with avelumab, an anti-PD-1 antibody, has improved the survival outcomes of patients. This review provides an overview of the treatment of aUC, including promising new therapeutic modalities and their potential impact on clinical outcomes.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Joep de Jong, Begona Valderrama, Julia Perera, Nuria Juanpere, Paloma Cejas, Henry Long, Mar Alba, Ewan Gibb, Joaquim Bellmunt
JOURNAL OF UROLOGY
(2022)
Meeting Abstract
Oncology
Shilpa Gupta, Joaquim Bellmunt, Elizabeth R. Plimack, Guru P. Sonpavde, Petros Grivas, Andrea B. Apolo, Sumanta K. Pal, Arlene O. Siefker-Radtke, Thomas W. Flaig, Matt D. Galsky, Jonathan E. Rosenberg
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Urology & Nephrology
Angela Estevez, Sumedh Kaul, Aaron Fleishman, Ruslan Korets, Peter Chang, Andrew Wagner, Joaquim Bellmunt, Aria Olumi, Heidi Rayala, Boris Gershman
JOURNAL OF UROLOGY
(2022)
Meeting Abstract
Urology & Nephrology
J. J. De Jong, B. P. Valderrama, J. Perera, J. Nuria, P. Cejas, H. Long, M. Alba, E. A. Gibb, J. Bellmunt
